Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
HEALEY ALS Platform Trial

Weekly Q&A – June 8, 2023
Guest Speaker

Brandy Quarles, MPH
Research Operations Coordinator
Augusta University, Georgia
The insane family that makes up the Augusta University ALS Clinic
HEALEY ALS Platform Trial:

- Regimen A
- Regimen B
- Regimen C
- Regimen D
- Regimen E
- Regimen F
- Regimen G

Common Protocol and Shared Infrastructure

ENROLLMENT COMPLETE

ENROLLING

ENROLLING
53 Sites Currently Active for Regimen F

(as of 6/8/23)

Nova Southeastern University
Essentia Health
Texas Neurology
Mass General Hospital
University of Nebraska
Hospital for Special Care
Henry Ford Hospital
Augusta University
Beth Israel Deaconess
University of Texas HSC
University of Colorado
Loma Linda University
Ohio State University
Cedars Sinai Medical Center
Duke University
Wake Forest University
Saint Alphonsus
UMass Worcester
Lehigh Valley
Thomas Jefferson
University of South Florida
University of Pennsylvania
SUNY Upstate
University of Iowa
California Pacific Med Center
Houston Methodist
Vanderbilt University
University of Minnesota
Washington University
Barrow Neurological Institute
University of Miami
Temple University

University of Virginia
Johns Hopkins University
University of Southern CA
Holy Cross Hospital
University of Washington
University of Utah
Penn State Hershey
University of Michigan
University of Kansas
Stony Brook University
University of Cincinnati
Mayo Clinic Rochester
Northwestern University
Georgetown University
Kaiser, Los Angeles
University of Pittsburgh
Virginia Commonwealth
Med College Wisconsin
University of CA, San Fran
University of Florida, Gainesville
Providence Brain and Spine

Site Map & Contacts:
https://bit.ly/3g2NZr5
Enrollment Update: Regimen F (as of 6/8/23)

Participants randomized within RGF (enrollment goal ≈ 240)

Participants consented to Master Protocol since RGF initiated

Participants assigned to RGF

Thank You
for your partnership in ALS research
10 Sites Currently Active for Regimen G

- Nova Southeastern University
- Texas Neurology
- University of Colorado
- Essentia Health
- University of Pittsburgh
- Beth Israel Deaconess
- Mass General Hospital
- Ohio State University
- University of Michigan
- Hospital for Special Care

(as of 6/8/23)

https://bit.ly/3g2NZr5
We look forward to testing DNL343 for people with ALS. By starting enrollment for Regimen G, we are another step closer to establishing new and effective treatments for ALS.

Merit Cudkowicz, MD, MSc
Director, Sean M. Healey & AMG Center for ALS, Massachusetts General Hospital

List of Participating Sites

Many sites are expected to start enrolling for Regimen F soon. Sites marked "Recruiting" are currently enrolling participants.

Sites marked "Active, Not recruiting" are active in the Platform Trial (for example, they are following participants in ongoing regimens that have already completed enrollment) but are not enrolling new participants at this time.

<table>
<thead>
<tr>
<th>Site</th>
<th>State</th>
<th>Enrollment Status</th>
<th>Trial Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mayo Clinic Florida</td>
<td>FL</td>
<td>Active, Not recruiting</td>
<td>Jany Paulet!</td>
</tr>
<tr>
<td>Nova Southeastern University</td>
<td>FL</td>
<td>Recruiting</td>
<td>Donovan Mott</td>
</tr>
</tbody>
</table>

Contact a study team near you to discuss enrollment opportunities
Register Here:

https://bit.ly/3oubqBo

THE ALS ASSOCIATION/NORtheast ALS CONSORTIUM

Educational Webinar

UNDERSTANDING STATISTICAL AND CLINICAL SIGNIFICANCE

SPEAKERS

JINSY ANDREWS, MD, MSc
COLUMBIA UNIVERSITY

CHRISTINA FOURNIER, MD, MSc
EMORY UNIVERSITY

ERIC MACKLIN, PhD
HARVARD MEDICAL SCHOOL

THURSDAY | 15 JUNE
4:00 - 5:00 PM ET

What do researchers and scientists mean when they describe a study as “statistically significant?” How do people with ALS and clinicians understand whether or not a treatment option is “clinically significant?” This webinar and panel discussion will provide a framework for understanding the results of ALS clinical trials, using several recent studies as examples.
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: https://bit.ly/3r6Nd2L
ALS Link sign-up: https://bit.ly/3o2Ds3m

Upcoming Webinars:
June 15th- Weekly Q&A
June 22nd- Weekly Q&A and Lumbar Puncture Discussion with Shafeeq Ladha, MD
June 29th- Weekly Q&A with Hilda Gutierrez from Beth Israel Deaconess (Boston)